Alkermes Plc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alkermes Plc. on March 9, 2017. The report addresses a significant legal development regarding the company's product AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal event and does not contain financial performance data.
Material Changes and Legal Developments
- Patent Upheld: On March 9, 2017, the United States Patent and Trademark Office Patent Trials and Appeal Board upheld the validity of four Orange Book-listed patents (U.S. Patent Nos. 8,663,685, 8,440,703, 8,354,437, and 8,007,826) challenged via the inter partes review (IPR) process.
- Ongoing Litigation: These patents, along with U.S. Patent No. 5,540,938 (which was not part of the IPR), are also being challenged in the U.S. District Court for the District of Delaware.
- Court Status: The District Court has completed the trial of the case but has not yet issued a decision.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future outlook. The primary risk highlighted is the pending decision from the U.S. District Court for the District of Delaware regarding the validity of the AMPYRA patents.
Investor Verification Checklist
- Verify the status of the pending decision in the U.S. District Court for the District of Delaware regarding AMPYRA patents.
- Confirm the specific expiration dates of the upheld patents (Nos. 8,663,685, 8,440,703, 8,354,437, 8,007,826) and the non-IPR patent (No. 5,540,938).
- Monitor for any subsequent filings regarding the District Court's ruling.